

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 207A
Serial No. : to be assigned
Applicant: : Wang et al.
Date Filed : Concurrently herewith
For : METHODS OF USING IL-1
ANTAGONISTS TO TREAT
NEOINTIMAL HYPERPLASIA

Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	_____	_____	_____	_____	_____


OTHER DOCUMENTS

Examiner
Initials

XZ Rectenwald et al. (2000) Circulation 102: 1697-1702

EXAMINER
CONSIDERED

DATE




10/11/06


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



FORM PTO-1449

Att. Docket No. 207A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: : Wang et al.
Serial No. : 10/840,138
Date Filed : May 6, 2004
For : METHODS OF USING IL-1
ANTAGONISTS TO TREAT
NEOINTIMAL HYPERPLASIA
Examiner : To be Assigned
Group Art Unit : 1632

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
<u>XZ</u>	<u>5,135,917</u>	<u>Aug. 4, 1992</u>	<u>Ronald M. Burch</u>		

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
<u>XZ</u>	<u>WO 00/71753 A2</u>	<u>30 Nov 2000</u>	<u>PCT</u>		
<u>XZ</u>	<u>WO 93/24134</u>	<u>9 Dec 1993</u>	<u>PCT</u>		
<u>XZ</u>	<u>WO 00/18932</u>	<u>06 Apr. 2000</u>	<u>PCT</u>		

<u>XZ</u>	<u>WO 02/16436 A2</u>	<u>28 Feb. 2002</u>	<u>PCT</u>
<u>XZ</u>	<u>WO 04/022718 A2</u>	<u>18 Mar. 2004</u>	<u>PCT</u>


OTHER DOCUMENTS

Examiner
Initials

<u>XZ</u>	<u>US Patent Application Publication No. US 2001/0053764 A1, Publication Date: December 20, 2001; "Interleukin-1 Inhibitors in the Treatment of Diseases".</u>
<u>XZ</u>	<u>US Patent Application Publication No. US 2003/0026806 A1, Publication Date: February 6, 2003; "Antibodies and Other Selective IL-1 Binding Agents that Allow Binding to IL-1 Receptor But Not Activation Thereof".</u>

EXAMINER
CONSIDERED

DATE




10/11/06

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400